NEW YORK (GenomeWeb) – Synthetic Genomics and Gen9 today announced a licensing deal. 

The agreement provides Gen9 a non-exclusive worldwide license to SGI's Febit intellectual property estate. The technology, purchased in 2012 by SGI from Febit Holding, comprises three families of patents and patent applications covering synthetic genomic methods. They include methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA. SGI has been using the technology to develop gene synthesis applications. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.